{
    "name": "capreomycin",
    "comment": "Rx",
    "other_names": [
        "Capastat"
    ],
    "classes": [
        "Antitubercular Agents"
    ],
    "source": "https://reference.medscape.com/drug/capastat-capreomycin-342552",
    "pregnancy": {
        "common": [
            "Safety in pregnancy not determined; there are no adequate and well-controlled studies in pregnant women; therapy has been shown to be teratogenic in rats when given in doses 3 1/2 times human dose;. This drug should be used during pregnancy only if potential benefit justifies potential risk to fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised when this drug is administered to a nursing woman"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Use of capreomycin have been associated with worse clinical outcomes (ie, decreased effectiveness, increased mortality) compared to other parenteral therapy for pulmonary multidrug-resistant tuberculosis (MDR-TB)",
                "Reserve capreomycin for patients with MDR-TB resistant to IV aminoglycosides and have limited treatment options ",
                "Caution in patients with renal or preexisting auditory impairment; weigh risk of additional impairment of cranial nerve VIII and/or kidneys against benefits from therapy ",
                "Concomitant use of capreomycin and other IV antituberculosis agents (streptomycin, viomycin) are not recommended",
                "Use extreme caution if administered with other ototoxic or nephrotoxic drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin)"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Pregnancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution in renal impairment and history of allergic reactions",
                "Risk of hypokalemia",
                "Risk of rare but potentially fatal toxic nephritis",
                "May be associated with worse clinical outcomes, ie, decreased effectiveness and increased mortality, compared with other parenteral therapy for pulmonary MDR-TB",
                "Audiometric measurements and assessment of vestibular function should be performed prior to initiation of therapy and at regular intervals during treatment",
                "Peripheral neuromuscular blocking action attributed to other polypeptide antibiotics (colistin sulfate, polymyxin A sulfate, paromomycin, and viomycin) and to aminoglycoside antibiotics (streptomycin, dihydrostreptomycin, neomycin, and kanamycin) studied; a partial neuromuscular blockade was demonstrated after large intravenous doses of this drug; action was enhanced by ether anesthesia (as has been reported for neomycin) and antagonized by neostigmine"
            ],
            "specific": [
                {
                    "type": "Renal injury",
                    "description": [
                        "Renal injury, with tubular necrosis, elevation of blood urea nitrogen (BUN) or serum creatinine, andabnormal urinary sediment, noted; slight elevation of BUN and serum creatinine observed in a significant number of patients receiving prolonged therapy",
                        "The appearance of casts, red cells, andwhite cells in the urine has been noted in a high percentage of cases; elevation of BUN above 30mg/100 mL or any other evidence of decreasing renal function with or without a rise in BUN levels calls forcareful evaluation of patient, and dosage should be reduced or drug completely withdrawn",
                        "The clinical significance of abnormal urine sediment and slight elevation in the BUN (or serum creatinine) observed during long-term therapy has not been established"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate and capreomycin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atracurium",
            "description": {
                "common": "capreomycin increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cidofovir",
            "description": {
                "common": "capreomycin and cidofovir both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "capreomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "capreomycin and neomycin PO both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "capreomycin increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pancuronium",
            "description": {
                "common": "capreomycin increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "capreomycin increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimabotulinumtoxinB",
            "description": {
                "common": "capreomycin increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rocuronium",
            "description": {
                "common": "capreomycin increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "capreomycin increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vecuronium",
            "description": {
                "common": "capreomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir and capreomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adefovir",
            "description": {
                "common": "adefovir and capreomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin and capreomycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "capreomycin and carboplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cephaloridine",
            "description": {
                "common": "capreomycin and cephaloridine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "capreomycin and cisplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colistin",
            "description": {
                "common": "capreomycin and colistin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "contrast media (iodinated)",
            "description": {
                "common": "capreomycin and contrast media (iodinated) both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "capreomycin and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and capreomycin both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "capreomycin and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "capreomycin and gentamicin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, capreomycin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Monitor renal function."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "capreomycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioversol",
            "description": {
                "common": "capreomycin and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "capreomycin and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "capreomycin and polymyxin B both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "capreomycin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptozocin",
            "description": {
                "common": "capreomycin and streptozocin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "capreomycin and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teicoplanin",
            "description": {
                "common": "capreomycin and teicoplanin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "capreomycin and tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "capreomycin and tobramycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, capreomycin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "foscarnet",
            "description": {
                "common": "capreomycin and foscarnet both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methoxyflurane",
            "description": {
                "common": "capreomycin and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paromomycin",
            "description": {
                "common": "capreomycin and paromomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentamidine",
            "description": {
                "common": "capreomycin and pentamidine both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptomycin",
            "description": {
                "common": "capreomycin and streptomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vancomycin",
            "description": {
                "common": "capreomycin and vancomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nephrotoxicity",
            "percent": "36"
        },
        {
            "name": "incr BUN",
            "percent": "11"
        },
        {
            "name": "Hearing loss",
            "percent": "3"
        },
        {
            "name": "subclinical",
            "percent": "5"
        },
        {
            "name": "clinical",
            "percent": null
        },
        {
            "name": "Eosinophilia",
            "percent": null
        },
        {
            "name": "dose related",
            "percent": null
        },
        {
            "name": "Incr LFTs",
            "percent": null
        },
        {
            "name": "Inj site pain",
            "percent": null
        },
        {
            "name": "induration",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Maculopapular rash",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}